NASDAQ:SIGA - Nasdaq - US8269171067 - Common Stock - Currency: USD
SIGA TECHNOLOGIES INC
NASDAQ:SIGA (2/10/2025, 8:23:02 PM)
After market: 6.4 +0.33 (+5.44%)6.07
+0.22 (+3.76%)
The current stock price of SIGA is 6.07 USD. In the past month the price decreased by -2.25%. In the past year, price increased by 17.86%.
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Japan approves SIGA's TEPOXX for smallpox, mpox, and cowpox, expanding antiviral availability for orthopoxviruses with proven safety and efficacy.
Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno...
Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy...
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 66.84 | 824.85B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 26.55 | 372.57B | ||
JNJ | JOHNSON & JOHNSON | 15.44 | 371.35B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.13 | 225.33B | ||
MRK | MERCK & CO. INC. | 11.31 | 218.56B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.63 | 213.62B | ||
PFE | PFIZER INC | 8.32 | 146.61B | ||
SNY | SANOFI-ADR | 13.45 | 133.58B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.71 | 112.62B | ||
ZTS | ZOETIS INC | 29.85 | 77.56B | ||
GSK | GSK PLC-SPON ADR | 7.91 | 74.41B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 30.52 | 42.58B |
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 45 full-time employees. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The firm's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. The company uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.
SIGA TECHNOLOGIES INC
31 East 62Nd Street
New York City NEW YORK 10065 US
CEO: Phillip L. Gomez
Employees: 45
Company Website: https://www.siga.com/
Investor Relations: https://investor.siga.com/
Phone: 12126729100
The current stock price of SIGA is 6.07 USD.
The exchange symbol of SIGA TECHNOLOGIES INC is SIGA and it is listed on the Nasdaq exchange.
SIGA stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for SIGA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of SIGA.
SIGA has a dividend yield of 10.26%. The yearly dividend amount is currently 0.45.
SIGA will report earnings on 2025-02-27, after the market close.
The PE ratio for SIGA is 5.06. This is based on the reported non-GAAP earnings per share of 1.2 and the current share price of 6.07 USD.
The outstanding short interest for SIGA is 8.39% of its float.
ChartMill assigns a technical rating of 1 / 10 to SIGA. When comparing the yearly performance of all stocks, SIGA is one of the better performing stocks in the market, outperforming 70.7% of all stocks.
ChartMill assigns a fundamental rating of 8 / 10 to SIGA. SIGA scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Over the last trailing twelve months SIGA reported a non-GAAP Earnings per Share(EPS) of 1.2. The EPS decreased by 1814.29% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 49.33% | ||
ROA | 43.87% | ||
ROE | 50.58% | ||
Debt/Equity | 0 |
For the next year, analysts expect an EPS growth of 12.74% and a revenue growth 44.62% for SIGA